CMS “Anemia Management” Quality Measure Relies on Monthly ESA/Hemoglobin Reports and Transfusion Level Monitoring
This article was originally published in RPM Report
Executive Summary
CMS taking a watch-and-monitor approach to controlling the use of ESAs in dialysis for 2013. That approach steps back from the trend of the past few years to specify more restrictive treatment levels to drive down further use of the products and represents a long, hard-fought success by Amgen and J&J to redefine the safety debate from when to use ESAs to efforts to avoid transfusions.